Merck has gained access to MorphoSys’ proprietary technologies, HuCal gold and AutoCal, for use in its drug discovery programs, and will be able to develop HuCal-derived therapeutic antibodies in a range of indications.
In return for the use of the technology MorphoSys is to receive an up-front payment, annual user fees and R&D funding. MorphoSys is also eligible to receive license and milestone payments on projects in clinical development, and royalties on any end-products emerging from the collaboration. Further financial details were not disclosed.
“We expect our agreement with MorphoSys to play a key role in building Merck’s capabilities for developing novel therapeutics in the biologics area,” said Dr John Shiver, vice president and head of Merck vaccines and biologics research.